In a broadened, interdisciplinary effort, using the combined capabilities of theoretical and synthetic chemistry, receptor pharmacology and animal testing, we plan to continue to (1) identify and calculate conformational and electronic properties of families of opiate narcotic analgesics, and understand the fundamental features of opiate-receptor interaction leading to agonism and antogonism, and (2) identify common features of diverse classes of chemical compounds leading to high affinity and activity at similar receptor sites. Specifically, the four primary aims during the proposed renewal period are: (1) Continue to test our hypotheses of the origin of agonist and antogonist activities in three classes of flexible opiates, by synthesis, receptor binding, and in vivo testing of promising 3- and 4-phenylpiperidines and opioid deptide analogs selected--as were those tested during the current period--from results of theoretical studies. (2) Calculate electronic properties, particularly electrostatic potential mapping for a) overlapping pharmacophores of diverse classes of opiates originally chosen on the basis of conformational properties alone and b) three classes of fused ring opiates in conjunction with receptor-binding studies: oxymorphones with N-substituent variation; oripavines with C7-tertiary alcohol substituent variation; and N-CH3 benzomorphans with C9Beta-alkanone variation for which conformational properties alone could not account for observed agonist/antagonist potency ratio variations. 3) Begin systematic studies of longer peptide opiates, particularly fragments of an substitution in Beta-endorphins, including theoretical, synthetic, and receptor-binding studies, to identify general conformational features that determine relative receptor affinity and analgesic activity. (4) Use of detailed receptor binding studies coupled with computer-assisted data analysis: a) to determine the molecular nature of the """"""""sodium effect"""""""" and its relevance to relative agonism and antagonism; b) to investigate the utility of naloxazone to identify proposed """"""""Mu1"""""""" analgesic receptors; and c) use kinetic experiments to investigate the validity of a recently proposed opiate receptor complex.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA002622-08
Application #
3207459
Study Section
(DABB)
Project Start
1980-03-01
Project End
1988-01-31
Budget Start
1987-01-01
Budget End
1988-01-31
Support Year
8
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Sri International
Department
Type
DUNS #
City
Menlo Park
State
CA
Country
United States
Zip Code
94025
Morgan, Judith K; Shaw, Daniel S; Olino, Thomas M et al. (2016) History of Depression and Frontostriatal Connectivity During Reward Processing in Late Adolescent Boys. J Clin Child Adolesc Psychol 45:59-68
Martin, Monica J; Conger, Rand D; Sitnick, Stephanie L et al. (2015) Reducing Risk for Substance Use by Economically Disadvantaged Young Men: Positive Family Environments and Pathways to Educational Attainment. Child Dev 86:1719-37
Morgan, Judith K; Shaw, Daniel S; Forbes, Erika E (2015) Fearfulness moderates the link between childhood social withdrawal and adolescent reward response. Soc Cogn Affect Neurosci 10:761-8
Morgan, Judith K; Shaw, Daniel S; Forbes, Erika E (2014) Maternal depression and warmth during childhood predict age 20 neural response to reward. J Am Acad Child Adolesc Psychiatry 53:108-117.e1
Filizola, M; Laakkonen, L; Loew, G H (1999) 3D modeling, ligand binding and activation studies of the cloned mouse delta, mu;and kappa opioid receptors. Protein Eng 12:927-42
Huang, P; Kim, S; Loew, G (1997) Development of a common 3D pharmacophore for delta-opioid recognition from peptides and non-peptides using a novel computer program. J Comput Aided Mol Des 11:21-8
Maguire, P A; Loew, G H (1996) Thermodynamics of ligand binding to the cloned delta-opioid receptor. Eur J Pharmacol 318:505-9
Alkorta, I; Loew, G H (1996) A 3D model of the delta opioid receptor and ligand-receptor complexes. Protein Eng 9:573-83
Chen, S W; Maguire, P A; Davies, M F et al. (1996) Evidence for mu1-opioid receptor involvement in fentanyl-mediated respiratory depression. Eur J Pharmacol 312:241-4
Chao, T M; Perez, J J; Loew, G H (1996) Characterization of the bioactive form of linear peptide antagonists at the omega-opioid receptor. Biopolymers 38:759-68

Showing the most recent 10 out of 27 publications